It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AVDL’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AVDL’s TA Score shows that 6 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).
AVDL (@Pharmaceuticals: Other) experienced а -0.77% price change this week, while NBIX (@Pharmaceuticals: Other) price change was +6.88% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.34%. For the same industry, the average monthly price growth was -0.19%, and the average quarterly price growth was -10.14%.
AVDL is expected to report earnings on Mar 13, 2025.
NBIX is expected to report earnings on Feb 11, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
AVDL | NBIX | AVDL / NBIX | |
Capitalization | 1.53B | 13.7B | 11% |
EBITDA | -149.12M | 358M | -42% |
Gain YTD | -26.983 | 2.778 | -971% |
P/E Ratio | N/A | 57.20 | - |
Revenue | 28M | 1.89B | 1% |
Total Cash | 105M | 1.03B | 10% |
Total Debt | 2.62M | 428M | 1% |
AVDL | NBIX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 61 | 68 | |
SMR RATING 1..100 | 98 | 53 | |
PRICE GROWTH RATING 1..100 | 82 | 44 | |
P/E GROWTH RATING 1..100 | 51 | 90 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NBIX's Valuation (79) in the Biotechnology industry is in the same range as AVDL (87) in the Medical Specialties industry. This means that NBIX’s stock grew similarly to AVDL’s over the last 12 months.
AVDL's Profit vs Risk Rating (61) in the Medical Specialties industry is in the same range as NBIX (68) in the Biotechnology industry. This means that AVDL’s stock grew similarly to NBIX’s over the last 12 months.
NBIX's SMR Rating (53) in the Biotechnology industry is somewhat better than the same rating for AVDL (98) in the Medical Specialties industry. This means that NBIX’s stock grew somewhat faster than AVDL’s over the last 12 months.
NBIX's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for AVDL (82) in the Medical Specialties industry. This means that NBIX’s stock grew somewhat faster than AVDL’s over the last 12 months.
AVDL's P/E Growth Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NBIX (90) in the Biotechnology industry. This means that AVDL’s stock grew somewhat faster than NBIX’s over the last 12 months.
AVDL | NBIX | |
---|---|---|
RSI ODDS (%) | 3 days ago90% | 3 days ago62% |
Stochastic ODDS (%) | 3 days ago85% | 3 days ago56% |
Momentum ODDS (%) | 3 days ago86% | 3 days ago72% |
MACD ODDS (%) | 3 days ago82% | 3 days ago67% |
TrendWeek ODDS (%) | 3 days ago83% | 3 days ago70% |
TrendMonth ODDS (%) | 3 days ago84% | 3 days ago72% |
Advances ODDS (%) | 11 days ago82% | 6 days ago71% |
Declines ODDS (%) | 4 days ago83% | 4 days ago63% |
BollingerBands ODDS (%) | 3 days ago78% | 3 days ago70% |
Aroon ODDS (%) | 3 days ago85% | 3 days ago76% |
A.I.dvisor tells us that AVDL and PROC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVDL and PROC's prices will move in lockstep.
Ticker / NAME | Correlation To AVDL | 1D Price Change % | ||
---|---|---|---|---|
AVDL | 100% | +1.98% | ||
PROC - AVDL | 30% Poorly correlated | +2.87% | ||
ITCI - AVDL | 29% Poorly correlated | -0.82% | ||
RMTI - AVDL | 29% Poorly correlated | +1.46% | ||
PAHC - AVDL | 25% Poorly correlated | -0.55% | ||
LIEN - AVDL | 24% Poorly correlated | +0.98% | ||
More |
A.I.dvisor tells us that NBIX and ACET have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ACET's prices will move in lockstep.
Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
---|---|---|---|---|
NBIX | 100% | +0.34% | ||
ACET - NBIX | 25% Poorly correlated | +5.78% | ||
AVDL - NBIX | 23% Poorly correlated | +1.98% | ||
SNDL - NBIX | 23% Poorly correlated | +4.05% | ||
IMCC - NBIX | 23% Poorly correlated | +4.00% | ||
ZOM - NBIX | 23% Poorly correlated | +4.42% | ||
More |